Estados Unidos · Agencias y tiempo real · PR Newswire

Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026

Publicado por PR Newswire · Estados Unidos hace 2 h

~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026

También te puede interesar

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026

Compartir

También te puede interesar

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Infinity Hires Meta Superintelligence Labs Chip Veteran and the CUDA Educator Who's Taught Two Million Engineers

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows